CryoPort (NASDAQ:CYRX) Stock Rating Lowered by Wall Street Zen

Key Points

• CryoPort (NASDAQ:CYRX) was downgraded by Wall Street Zen from a "hold" to a "sell," though the analyst mix remains mixed with seven Buys, one Hold and one Sell, giving a consensus rating of "Moderate Buy" and a consensus target price of $13.31.
• In its latest quarter CryoPort reported EPS of -$0.21 (missing estimates by $0.02) while revenue beat at $45.45 million, and the stock trades around $10.35 with a 12‑month range of $5.31–$11.45, a market cap of about $520 million and a P/E of 7.84.
• Insiders have been sellers recently (38,700 shares sold by the CFO and 59,939 shares sold total last quarter, ~ $471k), insiders now own 10% of the stock, and institutional/hedge fund ownership is very high at ~92.9%.

CryoPort (NASDAQ:CYRX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Sunday.

Other analysts also recently issued reports about the stock. Needham & Company LLC lifted their price objective on shares of CryoPort from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of CryoPort in a report on Friday, March 27th. Finally, Craig Hallum assumed coverage on shares of CryoPort in a report on Monday, March 30th. They set a "buy" rating and a $15.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CryoPort presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.31.

CryoPort Stock Up 0.9%

NASDAQ CYRX opened at $10.35 on Friday. The stock has a fifty day simple moving average of $8.92 and a 200 day simple moving average of $9.32. CryoPort has a twelve month low of $5.31 and a twelve month high of $11.45. The company has a market capitalization of $519.57 million, a price-to-earnings ratio of 7.84 and a beta of 1.75.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. The business had revenue of $45.45 million during the quarter, compared to analysts' expectations of $42.92 million. Research analysts expect that CryoPort will post -0.73 earnings per share for the current fiscal year.

Insider Buying and Selling at CryoPort

In related news, CFO Robert Stefanovich sold 38,700 shares of the business's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $7.76, for a total transaction of $300,312.00. Following the transaction, the chief financial officer owned 255,701 shares in the company, valued at $1,984,239.76. The trade was a 13.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark W. Sawicki sold 3,235 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total transaction of $25,880.00. Following the transaction, the insider owned 103,697 shares in the company, valued at $829,576. This represents a 3.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 59,939 shares of company stock worth $471,183. 10.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CryoPort

Several hedge funds and other institutional investors have recently modified their holdings of CYRX. AQR Capital Management LLC increased its position in shares of CryoPort by 285.5% during the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company's stock valued at $1,597,000 after buying an additional 194,482 shares during the period. Creative Planning purchased a new position in shares of CryoPort during the second quarter valued at about $96,000. Rhumbline Advisers increased its position in shares of CryoPort by 17.6% during the second quarter. Rhumbline Advisers now owns 92,098 shares of the company's stock valued at $687,000 after buying an additional 13,778 shares during the period. American Century Companies Inc. increased its position in shares of CryoPort by 24.4% during the second quarter. American Century Companies Inc. now owns 88,876 shares of the company's stock valued at $663,000 after buying an additional 17,459 shares during the period. Finally, Prudential Financial Inc. purchased a new position in shares of CryoPort during the second quarter valued at about $254,000. Hedge funds and other institutional investors own 92.90% of the company's stock.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.